Long-term gantenerumab Alzheimer’s trial halted due to ‘no regulatory path’

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer’s disease (DIAD). Gantenerumab was associated with serious safety concerns, including a high incidence of brain bleeding and swelling, possibly leading to an early study termination.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup